Guideline recommends Xolair to treat chronic urticaria.- Novartis.
A new global guideline on chronic urticaria (CU) recommends Xolair (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU), for patients who are not responding to antihistamines. Xolair is the only licensed treatment option for CSU, a type of CU, for patients unresponsive to antihistamines. CU, including CSU, is a severe disease that causes itchy, persistent hives and painful swelling.
The guideline recommends Xolair as the only treatment qualified with very good efficacy and very good safety in CSU. The guideline was endorsed by key dermatologic and allergy professional medical societies around the world.
30 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.